James is the founder and CEO of LabGenius, a next-generation antibody discovery company. LabGenius has pioneered the development of an ML-driven protein engineering platform that’s capable of designing, conducting and critically learning from its own experiments. As CEO, James has raised >$30M in financing from top-tier VCs (e.g. Lux Capital, Obvious Ventures, Atomico and Kindred) and struck R&D deals with top pharma companies like Sanofi. Prior to founding LabGenius, James completed a PhD at Imperial where he developed novel methods for re-engineering protein nanocages for targeted drug delivery. James is a recognised thought leader having spoken on the world stage at events like Milken Global Conference, TEDMED, RAAIS and CogX. James also plays an active role in briefing policymakers in government on AI-enabled drug discovery. Outside work, James is an active Angel Investor and has had the good fortune to back several of Europe’s most exciting deep-tech startups.